Xencor

Xencor CROIC

The Cash Return on Invested Capital (CROIC) of Xencor (XNCR) as of Oct 27, 2026 is -18.23 %. In the previous year, Cash Return on Invested Capital (CROIC) was -24.76 % — a change of -26.39% (higher).

CROIC

-18.23 %

YoY

-26.39%

Last updated:

Cash Return on Invested Capital (CROIC) of Xencor is 2025 -18.23 % . Cash Return on Invested Capital (CROIC) of Xencor was 2024 -24.76 % . It decreases by -26.39% higher compared to the previous year.

The Xencor CROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CROIC
Date
CROIC
Jan 1, 2018
-17.04 USD
Jan 1, 2019
8.99 USD
Jan 1, 2020
-3.28 USD
Jan 1, 2021
-4.48 USD
Jan 1, 2022
-2.60 USD
Jan 1, 2023
7.44 USD
Jan 1, 2024
-24.76 USD
Jan 1, 2025
-18.23 USD
The Xencor CROIC history
YEARCROICYoY
-18.23 %-26.39%
-24.76 %-432.90%
7.44 %-386.00%
-2.60 %-41.90%
-4.48 %+36.50%
-3.28 %-136.47%
8.99 %-152.76%
-17.04 %+17.34%
-14.52 %-149.77%
29.18 %+106.15%
14.15 %-135.51%
-39.87 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Xencor Stock analysis

What does Xencor do? The company Xencor Inc was founded in 1997 and has since become a significant biotechnology company specializing in the development of therapeutic proteins. Xencor's goal is to develop innovative and tailored therapies for the treatment of serious diseases such as cancer and autoimmune diseases. The company is headquartered in Monrovia, California, and employs a growing number of scientists, engineers, and other professionals specialized in the development of new themes and products. Xencor has acquired a variety of patents over the years to protect its intellectual property. Its business model is based on the development of new therapeutics through its proprietary XmAb technology platform, which enables the production of highly specific polyclonal antibodies that can improve the efficiency and safety of disease treatments. Xencor has divided its business activities into various divisions, including the development of immuno-oncology products, autoimmune therapies, and new methods for the therapy of inflammatory bowel diseases. The company has developed a wide range of products, including a new class of therapeutic antibodies that mobilize and strengthen patients' own immune system to fight cancer cells. By combining these antibodies with other therapies, the effectiveness of the treatment can be further increased. In the autoimmune diseases division, Xencor has developed new therapeutics to better regulate patients' immune system and treat dangerous autoimmune conditions such as rheumatoid arthritis, multiple sclerosis, or lupus. Another focus of the company is the development of therapies for inflammatory bowel diseases such as ulcerative colitis or Crohn's disease. By developing specific antibodies involved in the inflammatory processes in the intestine, Xencor can contribute to improving the treatment of these conditions. Xencor aims to accelerate the development of new therapeutics while improving their efficacy and safety. With the help of its proprietary XmAb technology platform, the company is able to develop new drugs faster and more effectively than conventional methods. Through the combination of technology, research and development, and a high level of commitment, Xencor pursues its vision and has successfully established itself as one of the leading companies in the biotechnology industry. Xencor is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Xencor stock

Cash Return on Invested Capital (CROIC) of Xencor is -18.23 % in 2025.

Cash Return on Invested Capital (CROIC) of Xencor changed from -24.76 % to -18.23 %, representing a -26.39% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Return on Invested Capital (CROIC) Xencor since 2006 – with annual values, charts, and detailed analysis.

CROIC measures the cash return generated on invested capital. Unlike ROIC, it uses free cash flow instead of accounting earnings, providing a purer profitability measure.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Return on Invested Capital (CROIC)'s Xencor with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Return on Invested Capital (CROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Return on Invested Capital (CROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Xencor

All Key Metrics — Xencor